# Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

> **NCT01681576** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 72 (actual)

## Conditions studied

- Salt-sensitive Hypertension

## Interventions

- **DRUG:** Valsartan
- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT01681576
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2015-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01681576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01681576, "Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01681576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*